478 related articles for article (PubMed ID: 15730050)
21. High Prevalence of Iron Deficiency Despite Standardized High-Dose Iron Supplementation During Recombinant Erythropoietin Therapy in Extremely Low Gestational Age Newborns.
Siddappa AM; Olson RM; Spector M; Northrop E; Zamora T; Brearley AM; Georgieff MK; Rao R
J Pediatr; 2020 Jul; 222():98-105.e3. PubMed ID: 32418819
[TBL] [Abstract][Full Text] [Related]
22. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
Li WY; Chu TS; Huang JW; Wu MS; Wu KD
J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
[TBL] [Abstract][Full Text] [Related]
23. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.
Gunnell J; Yeun JY; Depner TA; Kaysen GA
Am J Kidney Dis; 1999 Jan; 33(1):63-72. PubMed ID: 9915269
[TBL] [Abstract][Full Text] [Related]
24. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
[TBL] [Abstract][Full Text] [Related]
25. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
Movilli E; Cancarini GC; Vizzardi V; Camerini C; Brunori G; Cassamali S; Maiorca R
J Nephrol; 2003; 16(4):546-51. PubMed ID: 14696757
[TBL] [Abstract][Full Text] [Related]
26. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study.
Ogawa C; Tsuchiya K; Tomosugi N; Kanda F; Maeda K; Maeda T
PLoS One; 2017; 12(6):e0179608. PubMed ID: 28662118
[TBL] [Abstract][Full Text] [Related]
27. Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection.
Altintepe L; Kurtoglu E; Tonbul Z; Yeksan M; Yildiz A; Türk S
Clin Nephrol; 2004 May; 61(5):347-51. PubMed ID: 15182130
[TBL] [Abstract][Full Text] [Related]
28. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
29. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
Wang W; Zhang MH; Yu Y; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
[TBL] [Abstract][Full Text] [Related]
30. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
Daschner M; Mehls O; Schaefer F
Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
[TBL] [Abstract][Full Text] [Related]
31. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
32. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
[TBL] [Abstract][Full Text] [Related]
33. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
34. Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.
do Sameiro-Faria M; Ribeiro S; Rocha-Pereira P; Fernandes J; Reis F; Bronze-da-Rocha E; Miranda V; Quintanilha A; Costa E; Belo L; Santos-Silva A
Ren Fail; 2013; 35(10):1392-8. PubMed ID: 23991655
[TBL] [Abstract][Full Text] [Related]
35. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
36. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
37. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients.
Borawski J; Pawlak K; Myśliwiec M
Nephron; 2002 Aug; 91(4):671-81. PubMed ID: 12138272
[TBL] [Abstract][Full Text] [Related]
39. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
40. Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis.
Yin P; Song Y; Li J
Bosn J Basic Med Sci; 2017 Nov; 17(4):333-338. PubMed ID: 28446125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
